Galapagos NV

Equities

GLPG

BE0003818359

Biotechnology & Medical Research

Market Closed - Euronext Amsterdam Other stock markets 11:35:19 2024-06-26 EDT			After market 12:02:09
23.4 ^EUR	-2.66%		23.48	+0.34%

06-25	Frontier Medicines Corporation announced that it has received $99.999997 million in funding from a group of investors	CI
06-14	Galapagos Plans to Present 'Encouraging' Results for GLPG5101 in Non-Hodgkin Lymphoma	MT

Galapagos : Galapagos presents encouraging new data for CD19 CAR T candidate GLPG5101 in non Hodgkin lymphoma at EHA 2024

June 17, 2024 at 02:36 am

Galapagos NV

Galapagos NV

Below you will find information from the register publication of inside information. The information has been provided by the organisation.

Registration date16 jun 2024 - 18:34

Statutory nameGalapagos NV

TitleGalapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024

Previous result

Next result

Related downloads

202406160000000001_press-release-glpg-eha-2024-eng-final.pdf(opens in a new window)

202406160000000001_press-release-glpg-eha-2024-nl-final.pdf(opens in a new window)

Date last update: 17 June 2024

Attachments

Original Link
Permalink

Disclaimer

Galapagos NV published this content on 16 June 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 June 2024 06:35:02 UTC.

Latest news about Galapagos NV

Frontier Medicines Corporation announced that it has received $99.999997 million in funding from a group of investors	06-24	CI
Galapagos Plans to Present 'Encouraging' Results for GLPG5101 in Non-Hodgkin Lymphoma	06-14	MT
Galapagos NV Presents Encouraging New Data for CD19 CAR-T Candidate GLPG5101 in Non-Hodgkin Lymphoma at EHA 2024	06-14	CI
Galapagos, Adaptimmune to Jointly Develop Head, Neck Cancer Treatment	05-31	MT
Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug	05-31	MT
Galapagos and Adaptimmune Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-Cell Therapy Candidate, uza-cel	05-30	CI
Galapagos Partners with Blood Centers of America to Decentralize CAR-T Cell Therapy Manufacture	05-16	MT
Galapagos and Blood Centers of America Announce Strategic Collaboration to Accelerate Galapagos? Decentralized Car-T Manufacturing Network in the U.S	05-15	CI
Transcript : Galapagos NV, Q1 2024 Earnings Call, May 03, 2024	05-03
Galapagos NV Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Galapagos Showcases Innovative Approach in Hematological Cancer Care with Clinical and Translational Data Presentations at EBMT Congress 2024	04-08	CI
Galapagos Continues to be 'Value Trap' With Unclear Growth Path, BofA Says	03-28	MT
BofA Securities Downgrades Galapagos to Underperform From Neutral, Says 'Stock Remains a Value Trap'; Adjusts Price Target to $31 From $41	03-28	MT
Galapagos NV Announces Board Changes	03-27	CI
Galapagos to Seek Acquisitions	02-23	CI
Transcript : Galapagos NV, 2023 Earnings Call, Feb 23, 2024	02-23
Frontier Medicines Corporation announced that it has received $80.000001 million in its first tranche from Deerfield Management Company, L.P. Series C, DROIA nv, Galapagos NV, DCVC, MPM Asset Management, L.L.C., RA Capital Management, L.P. and other investors	02-21	CI
Galapagos NV Reports Earnings Results for the Full Year Ended December 31, 2023	02-21	CI
Galapagos NV to Present New Preliminary Translational Data at EBMT-EHA Annual Meeting 2024	02-15	CI
Galapagos Completes Sale of Jyseleca Business to Alfasigma	02-01	MT
Frontier Medicines Corporation announced that it expects to receive $99.999997 million in funding	01-30	CI
Alfasigma S.p.A. completed the acquisition of Filgotinib business from Galapagos NV.	01-30	CI
Galapagos NV Enters into Strategic Collaboration Agreement with Thermo Fisher Scientific, Inc. to Further Expand Its Decentralized CAR-T Manufacturing Network in the U.S	01-05	CI
Galapagos Partners with Thermo Fisher for Manufacturing in US	01-05	MT
Galapagos, Thermo Fisher Scientific to Establish Decentralized CAR-T Manufacturing Network	01-04	MT

Chart Galapagos NV

Duration

Period

More charts

Company Profile

Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. The company is committed to improving patients' lives worldwide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release

Related indices

BEL-20

More about the company

Income Statement Evolution

More financial data

Ratings for Galapagos NV

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

24.04 EUR

Average target price

36.73 EUR

Spread / Average Target

+52.79%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GALAPAGOS NV	-36.74%	1.7B
MODERNA, INC.	+31.11%	52.73B
LONZA GROUP AG	+37.49%	39B
IQVIA HOLDINGS INC.	-9.23%	38.52B
ALNYLAM PHARMACEUTICALS, INC.	+28.09%	30.38B
CELLTRION, INC.	-12.26%	26.39B
ICON PUBLIC LIMITED COMPANY	+11.28%	26.08B
UNITED THERAPEUTICS CORPORATION	+44.68%	14.15B
MEDPACE HOLDINGS, INC.	+32.67%	12.6B
BIO-TECHNE CORPORATION	-5.40%	11.51B

Other Biotechnology & Medical Research